Monitor the special shareholder meeting and regulatory (HSR) clearance timeline for Q3 2026 close. Vertex's large-cap profile and all-cash, non-contingent financing limit downside risk, but integration and pipeline execution risks remain. Watch for any competing bids or regulatory pushback.
Drugs in focus
VRTX drug pipeline →atumelnant
▲ Bullish Named in this 8-K- Impact
- Phase
- Phase 3 (CAH); Phase 1b/2a (ADCS)
- Time to market
- Estimated 2028 for CAH if Phase 3 succeeds (assuming ~1.5-2 year Phase 3 enrollment + regulatory review); ADCS indication is earlier-stage.
- Next catalyst
- None dated
What to watchWatch for CALM-CAH enrollment completion updates and any topline readout timeline guidance on upcoming quarterly earnings calls. The Phase 3 data is the make-or-break event, but the stock already has a commercial-stage floor from PALSONIFY revenue, reducing doomsday downside. Competitor Neurocrine's CRENESSITY is approved first, but early data suggests atumelnant may have a superior efficacy profile.
- ▲ PALSONIFY 4/10 Approved/Marketed (Phase 3 for carcinoid syndrome ongoing) Named in filing
- ▲ povetacicept 6/10 Filed/PDUFA (BLA under FDA review for accelerated approval in IgAN); Phase 3 (RAINIER in IgAN); Phase 2b/3 (OLYMPUS in p · PDUFA date Nov 30, 2026
- ● inaxaplin 5/10 Phase 2/3
- ▲ ALYFTREK 4/10 Approved
- ● JOURNAVX 4/10 Approved
- 7 more · All VRTX drugs, catalysts & trials →
How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Jul 7 $522.25entry
- T+1 · 4mo ago −4.56%α −4.25% · $498.43
- T+5 · 4mo ago −8.80%α −9.35% · $476.31
- T+20 · 4mo ago −9.87%α −11.20% · $470.72
- T+60 · 7w ago +0.11%α −1.89% · $522.81
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Vertex Pharmaceuticals announced a definitive agreement to acquire Crinetics Pharmaceuticals for $85.00 per share in cash, representing a total equity value of $10.0 billion ($8.8 billion net of cash). The deal adds PALSONIFY (approved, launched oral therapy for acromegaly) and atumelnant (Phase 3 oral ACTH receptor antagonist for congenital adrenal hyperplasia) to Vertex's pipeline, which it expects to generate over $5 billion in combined peak annual revenue. Vertex funded the transaction with cash on hand and a fully committed $4.5 billion bridge financing facility from Bank of America and Morgan Stanley; the deal is expected to close in Q3 2026 and become accretive to non-GAAP operating income in 2029.
Key Financial Metrics
Key Facts
- Vertex acquired Crinetics for $85.00 per share in cash, with a $10.0B equity valuation ($8.8B net of cash).
- The deal adds PALSONIFY, the first and only once-daily oral therapy for acromegaly (launched Oct. 2025, FDA and EMA approved), and atumelnant, a Phase 3 oral ACTH receptor antagonist for congenital adrenal hyperplasia (CAH).
- Vertex expects the combined assets to generate over $5 billion in annual peak revenue and the deal to become accretive to non-GAAP operating income in 2029.
- The merger is expected to close in Q3 2026, subject to Crinetics shareholder approval, HSR clearance, and other customary conditions.
- Vertex secured a $4.5 billion fully committed 364-day bridge loan facility from Bank of America and Morgan Stanley to finance the merger; the deal is not conditioned on financing.
- The termination fee payable by Crinetics to Vertex under specified circumstances is $350,474,425.
Financial Impact
$10.0B equity value ($8.8B net of cash); expects >$5B in combined peak annual revenue from acquired assets
Risk Factors
- Failure to obtain Crinetics shareholder approval or regulatory clearances (HSR, foreign)
- Integration challenges or slower-than-expected commercial uptake of PALSONIFY and atumelnant
- Execution risk in R&D pipeline for atumelnant and other early-stage assets
- Potential termination fee of $350.5M if the deal fails under certain circumstances
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-296710 |
| Document: d113650dex991.htm | 0001193125-26-296710 |
| Document: 0001193125-26-296710-index-headers.html | 0001193125-26-296710 |
| Document: 0001193125-26-296710-index.html | 0001193125-26-296710 |
| Document: 0001193125-26-296710.txt | 0001193125-26-296710 |
Track record
21 reports on VRTX
3 of 3 bullish or bearish reports moved the stock their way by T+5. Best: +10.87% at T+60 after the Feb 25, 2026 report. 3 of 3 went positive at some point.
Filters
- Nov 16, 2026today Insider Cluster Neutral 2/10 Entry $537.79 Now $531.45 −1.18% settles Nov 24
- Nov 16, 20261d ago 144 Neutral 2/10 Entry $543.10 Now $531.45 −2.15% settles Nov 23
- Nov 16, 20261d ago 144 Neutral 1/10 Entry $544.98 Now $531.45 −2.48% settles Nov 23
- Nov 13, 20263d ago SC 13G/A Neutral 2/10 Entry $542.00 Now $531.45 −1.95% settles Nov 23
- Nov 12, 20265d ago 144 Neutral 2/10 Entry $542.62 Now $531.45 −2.06% settles Nov 19
- Nov 6, 202611d ago 144 Neutral 2/10 Entry $547.09 to $538.60 Now $531.45 −2.86% ▼ −1.55% −4.15% vs SPY
- Nov 2, 202614d ago 8-K Bullish 6/10 Entry $530.76 to $547.89 Now $531.45 +0.13% ▲ +3.23% +3.81% vs SPY
- Oct 22, 202626d ago 3 Neutral 2/10 Entry $523.93 to $558.88 Now $531.45 +1.44% ▲ +6.67% +7.23% vs SPY
- Oct 20, 202628d ago 8-K Neutral 2/10 Entry $524.52 to $521.03 Now $531.45 +1.32% ▼ −0.67% −0.22% vs SPY
- Oct 16, 20264w ago Institutional Cluster Bullish 4/10 Entry $500.36 to $517.49 Now $531.45 +6.21% ▲ +3.42% +3.57% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers